Brandon Scalea

Articles

Pipeline Updates Advance Paradigms Across Lymphomas

May 31st 2019

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

Navigating the Complex Treatment Paradigm of Relapsed/Refractory Multiple Myeloma

May 31st 2019

Cristina Gasparetto, MD, discusses the rapidly evolving field of relapsed/refractory myeloma.

Langer Lends Insight on Transformed NSCLC Landscape

May 30th 2019

Corey J. Langer, MD, highlights how precision medicine has emerged in the treatment of patients with non–small cell lung cancer via targeted therapies and checkpoint inhibitors.

TAS-102 Expands Arsenal in Gastric Cancer, But Long Road Ahead for Research

May 24th 2019

Mark M. Zalupski, MD, sheds light on the current treatment landscape of advanced gastric cancer and the numerous challenges that remain.

Dostarlimab Demonstrates Efficacy in Endometrial Cancer

May 23rd 2019

Ana Oaknin, MD, provides insight into the implications of the GARNET trial and the promise of dostarlimab in endometrial cancer.

Pembrolizumab Shows Promise for Unmet Need in NMIBC

May 22nd 2019

Arjun V. Balar, MD, highlights the KEYNOTE-057 study findings and provided insight into the role of immunotherapy in bladder cancer.

Immunotherapy Lessons Learned in Melanoma May Turn Tide in Other Tumors

May 22nd 2019

The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.

Optimal Sequencing Next Step Following Rapid Progress in HCC

May 22nd 2019

Gazala N. Khan, MD, highlights the recent headway made in hepatocellular carcinoma and discusses the remaining challenges.

Shedding Light on the Challenging Pancreatic Cancer Paradigm

May 20th 2019

Vaibhav Sahai, MBBS, sheds light on ongoing research in metastatic pancreatic cancer and discusses the role of genomic profiling in the space.

Navigating Complexities of Localized Pancreatic Cancer, NETs

May 17th 2019

Philip A. Philip, MD, PhD, FRCP, discusses recent studies that have impacted locally advanced pancreatic cancer treatment and shared key updates in the neuroendocrine tumors paradigm.

NGS Enables Individualized Treatment Approach in Oncology

May 16th 2019

Steven N. Kalkanis, MD, explains how next-generation sequencing testing fits into cancer treatment today and efforts that need to be made to enable its widespread use in the future.

Shields Sheds Light on Complex mCRC Landscape

May 16th 2019

Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.

Combination Prophylactic Approach Is Best for Neratinib-Associated Diarrhea in HER2+ Breast Cancer

May 14th 2019

Lauren Nye, MD, discusses the promise of neratinib in patients with early HER2-positive breast cancer, as well as ways to ease concern of associated toxicity.

Expert Says Neratinib-Associated Diarrhea Manageable in HER2+ Breast Cancer

May 10th 2019

Michel Velez, MD, addresses how loperamide and other methods of prophylaxis are significantly reducing the risk of neratinib-associated diarrhea in patients with HER2-positive breast cancer.

Future Looks Bright for CAR T-Cell Therapies in Hematologic Malignancies

May 8th 2019

Nirav N. Shah, MD, discusses the promise of CAR T-cell therapy in hematologic malignancies and highlights recent research exploring sequential CAR-T therapies, armored CAR T cells, as well as other novel approaches.

Frontline Advances Propel Progress in Multiple Myeloma

May 7th 2019

Parameswaran Hari, MD, MRCP, discusses the rapidly evolving paradigm of myeloma with a focus on the latest updates in the frontline setting.

Genomic Assays Continue to Individualize Treatment for HR+ Breast Cancer

May 7th 2019

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

Navigating the Complexities of Tumor Sidedness in Colorectal Cancer

May 7th 2019

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided colorectal cancer and highlights recent research on tumor sidedness and its impact on clinical practice.

Emerging Agents Spur Optimism in Myeloma

May 7th 2019

Saurabh Chhabra, MD, MS, highlights emerging agents in the field of relapsed/refractory myeloma that have oncologists optimistic for the future.

Ruxolitinib Combos Explored to Address MPN-Associated Symptoms

May 6th 2019

Laura Michaelis, MD, highlights the many ruxolitinib combinations under investigation and provided insight into the role of interferon in myeloproliferative neoplasms.